Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
Table 5
Frequencies and percentages of linkage between HLA alleles (haplotypes) in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.
Haplotypes
HCV Patients ()
Healthy controls ()
PC
Responders
NonResponders
PC
DQB1*0201-DQB1*0202
28 (45.2%)
20 (35.1%)
0.078
18 (47.4%)
10 (50%)
0.534
DQB1*0202-DQB1*0205
7 (11.3%)
10 (17.5%)
0.695
6 (15.8%)
1 (5%)
0.226
DQB1*0204-DQB1*0301
14 (22.6%)
12 (21.1%)
1.000
9 (23.7%)
5 (25%)
0.577
DQB1*0204-DQB1*0313
3 (4.8%)
8 (14.1%)
0.567
0 (0%)
3 (15 %)
0.037#
DQB1*0309-DQB1*0313
7 (8.1%)
6 (10.5%)
1.000
2 (5.3%)
5 (25%)
0.041#
DQB1*0309-DQB1*0319
25 (40.3%)
18 (31.6%)
0.085
16 (42.1%)
9 (45%)
0.525
DQB1*0313-DQB1*0319
7 (11.3%)
6 (10.5%)
1.000
2 (5.3%)
5 (25%)
0.041#
DQB1*0603-DQB1*0628
10 (16.2%)
7 (12.3%)
0.447
8 (21.1%)
2 (10%)
0.250
DRB1*0301-DRB1*0318
8 (12.9%)
2 (3.5%)
0.087
6 (14.6%)
2 (9.5%)
0.447
DRB1*0706-DRB1*0711
4 (6.5%)
11 (19.3%)
0.084
2 (4.9%)
2 (9.5%)
0.417
DRB1*1301-DRB1*1328
7 (11.3%)
10 (17.5%)
0.695
7 (17.1%)
0 (0%)
0.046#
DRB1*1301-DRB1*1361
7 (11.3%)
12 (21.1%)
0.219
7 (17.1%)
0 (0%)
0.046#
DRB1*1301-DRB1*1369
7 (11.3%)
15 (26.3%)
0.089
7 (17.1%)
0 (0%)
0.046#
DRB1*1328-DRB1*1361
7 (11.3%)
3 (5.3%)
0.325
7 (17.1%)
0 (0%)
0.046#
DRB1*1328-DRB1*1369
7 (11.3%)
9 (15.8%)
0.752
7 (17.1%)
0 (0%)
0.046#
Significant difference at PC ≤ 0.05; (corrected P after the Bonferroni correction) between responder and nonresponder patients to treatment. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “.”
